Psychological Support for IBD: What a Cochrane Review of 68 Studies Shows About Therapy, Education, and Relaxation

Living with inflammatory bowel disease means navigating not just physical symptoms but the sustained emotional weight of a chronic, unpredictable condition. Anxiety before procedures. Depression during flares. The mental effort of managing a body that does not always cooperate.

A 2025 update to a Cochrane systematic review — the highest recognised tier of evidence synthesis — set out to answer a direct question: do psychological interventions actually improve outcomes for people with IBD? After reviewing 68 randomised controlled trials involving more than 6,400 participants, the answer is: yes, modestly but reliably (Tiles-Sar et al., 2025).

Why Mental Health and IBD Are Connected

The Cochrane review notes that people with IBD carry an elevated risk of depression and anxiety, and the relationship is thought to operate in both directions: psychological distress can amplify the perceived burden of disease, while persistent physical symptoms contribute directly to low mood and worry. Neither axis can be fully addressed by treating only one of them.

This bidirectional relationship is why psychological support is a legitimate, evidence-based component of IBD care — not an optional add-on for patients who feel they are not coping well enough.

What the Evidence Shows for Adults

The review pooled data across 48 trials that reported results in sufficient detail for meta-analysis, covering 6,111 adults. Three broad types of intervention were examined separately.

Psychotherapy

Compared with usual care alone, psychotherapy produced small but meaningful improvements across three outcomes:

• Quality of life: standardised mean difference (SMD) 0.23 (95% CI 0.12 to 0.34; 20 trials, 1,572 participants; moderate-certainty evidence)
• Depression: SMD −0.27 (95% CI −0.39 to −0.16; 16 trials, 1,232 participants; moderate-certainty)
• Anxiety: SMD −0.29 (95% CI −0.40 to −0.17; 15 studies, 1,135 participants; moderate-certainty)

An SMD in the range of 0.2–0.3 is classified as small but clinically meaningful — corresponding to what patients typically describe as noticeably easier to manage, rather than a dramatic transformation. The consistency across such a large evidence base, with low statistical heterogeneity (I² of 13%, 0%, and 1% respectively), is what makes these findings reliable.

Most trials used multimodular approaches combining cognitive-behavioural therapy techniques with education or relaxation elements, which reflects how psychological support is typically delivered in practice.

Patient Education

Structured education programmes — designed to improve disease understanding, self-management skills, and confidence around treatment — also showed small positive effects:

• Quality of life: SMD 0.19 (95% CI 0.06 to 0.32; 12 trials, 1,058 participants; moderate-certainty)
• Depression: SMD −0.22 (95% CI −0.37 to −0.07; 7 studies, 765 participants; moderate-certainty)
• Anxiety: SMD −0.16 (95% CI −0.32 to 0.00; 6 studies, 668 participants; moderate-certainty)

The effects on anxiety sat at the lower boundary of statistical certainty, but the direction was consistent with the other intervention types.

Relaxation Techniques

Breathing exercises, guided imagery, mindfulness-based practices, and progressive muscle relaxation showed effects comparable to formal psychotherapy:

• Quality of life: SMD 0.25 (95% CI 0.08 to 0.41; 12 studies, 916 participants; moderate-certainty)
• Depression: SMD −0.18 (95% CI −0.35 to −0.02; 7 studies, 576 participants; moderate-certainty)
• Anxiety: SMD −0.26 (95% CI −0.43 to −0.09; 8 studies, 627 participants; moderate-certainty)

This finding is practically significant: relaxation techniques are among the most accessible interventions available — often delivered as apps, group programmes, or self-guided resources — and their evidence base holds up alongside formal therapy on the outcomes measured here.

What About Children and Adolescents?

For younger patients, the review found that multimodular psychotherapy programmes improved quality of life with a moderate effect size (SMD 0.54; 95% CI 0.06 to 1.02; 3 studies, 91 participants; moderate-certainty). Evidence for anxiety and depression in this age group was insufficient to draw clear conclusions.

What This Review Does Not Show

The review could not pool results for disease activity — how psychological interventions affect the physical course of IBD — because statistical heterogeneity across studies was too high (I² = 72%) to allow meaningful combination. This is an important boundary: psychological support improves how you feel and function, but it is not a substitute for appropriate medical treatment of IBD itself. The two work alongside each other.

What This Means in Practice

The consistent pattern across three very different types of intervention — formal psychotherapy, structured education, and relaxation techniques — points in the same direction: intentional attention to mental health produces measurable, reproducible benefits for adults living with IBD. The effect sizes are modest, but they are real, and they appear across multiple outcomes and dozens of independent trials.

The practical implication is not that everyone with IBD needs a psychologist. It is that if anxiety, depression, or the psychological weight of managing a chronic condition is affecting your quality of life, there are evidence-supported approaches available — and that raising this with your clinical team is a reasonable, justified step.

Consult your clinician. If anxiety, low mood, or stress related to your IBD is affecting your daily life, raise this with your gastroenterologist or IBD nurse. Referral to a psychologist or mental health professional with experience in chronic illness is an evidence-based part of integrated IBD care, not a secondary concern.